CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages.

MLA

Pietrobono, Silvia, et al. “CCL3 Predicts Exceptional Response to TGFβ Inhibition in Basal-like Pancreatic Cancer Enriched in LIF-Producing Macrophages.” NPJ Precision Oncology, vol. 8, no. 1, Oct. 2024, pp. 1–15. EBSCOhost, https://doi.org/10.1038/s41698-024-00742-3.

APA

Pietrobono, S., Bertolini, M., De Vita, V., Sabbadini, F., Fazzini, F., Frusteri, C., Scarlato, E., Mangiameli, D., Quinzii, A., Casalino, S., Zecchetto, C., Merz, V., & Melisi, D. (2024). CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages. NPJ Precision Oncology, 8(1), 1–15. https://doi.org/10.1038/s41698-024-00742-3

Chicago

Pietrobono, Silvia, Monica Bertolini, Veronica De Vita, Fabio Sabbadini, Federica Fazzini, Cristina Frusteri, Enza Scarlato, et al. 2024. “CCL3 Predicts Exceptional Response to TGFβ Inhibition in Basal-like Pancreatic Cancer Enriched in LIF-Producing Macrophages.” NPJ Precision Oncology 8 (1): 1–15. doi:10.1038/s41698-024-00742-3.